Technical Analysis for GILD - Gilead Sciences, Inc.

Grade Last Price % Change Price Change
grade B 69.18 0.77% 0.53
GILD closed up 0.77 percent on Friday, January 18, 2019, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Feb 4

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical GILD trend table...

Date Alert Name Type % Chg
Jan 18 Doji - Bearish? Reversal 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 50 DMA Support Bullish 0.77%
Jan 17 180 Bullish Setup Bullish Swing Setup 0.77%
Jan 17 Outside Day Range Expansion 0.77%
Jan 17 Overbought Stochastic Strength 0.77%
Jan 16 Stochastic Sell Signal Bearish 2.28%
Jan 16 50 DMA Support Bullish 2.28%
Jan 16 Overbought Stochastic Strength 2.28%
Jan 15 Crossed Above 50 DMA Bullish 0.96%

Older signals for GILD ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. The company also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, it provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. Further, it has product candidates in various stages for the treatment of cardiovascular diseases, respiratory diseases, and oncology diseases/inflammation. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, GSK, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Is GILD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 88.9107
52 Week Low 60.32
Average Volume 7,825,265
200-Day Moving Average 71.6875
50-Day Moving Average 67.5428
20-Day Moving Average 65.851
10-Day Moving Average 68.203
Average True Range 1.8603
ADX 19.09
+DI 19.4431
-DI 13.5877
Chandelier Exit (Long, 3 ATRs ) 63.9991
Chandelier Exit (Short, 3 ATRs ) 65.9009
Upper Bollinger Band 71.3842
Lower Bollinger Band 60.3178
Percent B (%b) 0.8
BandWidth 16.805212
MACD Line 0.5114
MACD Signal Line 0.0216
MACD Histogram 0.4897
Fundamentals Value
Market Cap 90.35 Billion
Num Shares 1.31 Billion
EPS 9.21
Price-to-Earnings (P/E) Ratio 7.51
Price-to-Sales 3.57
Price-to-Book 4.49
PEG Ratio -1.08
Dividend 2.08
Dividend Yield 3.01%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 70.79
Resistance 3 (R3) 70.74 70.16 70.52
Resistance 2 (R2) 70.16 69.75 70.18 70.43
Resistance 1 (R1) 69.67 69.50 69.38 69.72 70.34
Pivot Point 69.09 69.09 68.95 69.11 69.09
Support 1 (S1) 68.60 68.68 68.31 68.65 68.02
Support 2 (S2) 68.02 68.43 68.04 67.93
Support 3 (S3) 67.53 68.02 67.84
Support 4 (S4) 67.58